Vancomycin revisited - 60 years later

Frontiers in Public Health

Volumn 2, Issue OCT, 2014, Pages

  Rubinstein, Ethan ^a   Keynan, Yoav ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

"red man" syndrome; Dose; MRSA; Nephrotoxicity; Oral vancomycin; Safety; Vancomycin; VRE

Indexed keywords

EID: 85029379164     PISSN: None     EISSN: 22962565     Source Type: Journal    
DOI: 10.3389/fpubh.2014.00217     Document Type: Review

References (76)

1. Griffith RS. Introduction to vancomycin. Rev Infect Dis (1981) 3(Suppl):S200-4. doi:10.1093/clinids/3.Supplement.S200
2. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis (2006) 42(Suppl 1):S3-4. doi:10.1086/491708
3. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseasessociety of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis (2011) 52(3):e18-55. doi:10.1093/cid/ciq146
4. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, et al. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin Microbiol Infect (2013) 19(12):1163-8. doi:10.1111/1469-0691.12168
5. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2008) 52(1):192-7. doi:10.1128/AAC.00700-07
6. Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis (2007) 44(2):190-6. doi:10.1086/510386
7. Khatib R,Johnson LB,Fakih MG,RiedererK,Khosrovaneh A,Shamse Tabriz M, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis (2006) 38(1):7-14. doi:10.1080/ 00365540500372846
8. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis (2012) 54(Suppl 3):S214-9. doi:10.1093/cid/cir920
9. Brummett RE. Effects of antibiotic-diuretic interactions in the guinea pig model of ototoxicity. Rev Infect Dis (1981) 3(Suppl):S216-23. doi:10.1093/clinids/3. Supplement_2.S216
10. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother (1983) 23(1):138-41. doi:10.1128/AAC.23.1.138
11. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 94(3):343-6. doi:10.7326/0003-4819-94-3-343
12. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM,et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis (2003) 36(4):429-39. doi:10.1086/346207
13. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis (2001) 1(3):147-55. doi:10.1016/S1473- 3099(01)00091-3
14. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycinintermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 23(1):99-139. doi:10.1128/CMR.00042-09
15. Biavasco F, Vignaroli C, Varaldo PE. Glycopeptide resistance in coagulasenegative Staphylococci. Eur J Clin Microbiol Infect Dis (2000) 19(6):403-17. doi:10.1007/s100960000299
16. Strahilevitz J, Rubinstein E. Novel agents for resistant gram-positive infections - a review. Int J Infect Dis (2002) 6(Suppl 1):S38-46. doi:10.1016/S1201-9712(02) 90153-0
17. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol (2004) 42(6):2398-402. doi:10.1128/JCM.42.6.2398-2402.2004
18. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother (2008) 52(9):3315-20. doi:10.1128/ AAC.00113-08
19. Gómez J, García-Vázquez E, Baños R, Canteras M, Ruiz J, Baños V, et al. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis (2007) 26(4):239-45. doi:10.1007/s10096-007-0272-x
20. Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, et al. Predictive factors for mortality inpatients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect (2013) 19(11):1049-57. doi:10.1111/1469- 0691.12108
21. van Hal SJ, Lodise TP,Paterson DL. The clinical significanceof vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis (2012) 54(6):755-71. doi:10.1093/cid/ cir935
22. Zhuo C, Xu YC, Xiao SN, Zhang GY, Zhong NS. Glycopeptide minimum inhibitory concentration creep among methicillin-resistant Staphylococcus aureus from 2006-2011 in China. Int J Antimicrob Agents (2013) 41(6):578-81. doi:10.1016/j.ijantimicag.2013.02.014
23. Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centersfrom 2002to2006.Antimicrob AgentsChemother (2009) 53(10):4127-32. doi:10.1128/AAC.00616-09
24. Reynolds R, Hope R, Warner M, MacGowan AP, Livermore DM, Ellington MJ, et al. Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolatedinthe UKand Ireland 2001-07.J Antimicrob Chemother (2012) 67(12):2912-8. doi:10.1093/jac/dks324
25. Gould I M . Treatment of bacteraemia: methicillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA). Int J Antimicrob Agents (2013) 42(Suppl):S17-21. doi:10.1016/j.ijantimicag.2013.04.006
26. Machado DP, Goldani LZ, Paiva RM, Aquino VR, de-Paris F, Lisboa T, et al. The impact of serum vancomycin levels and minimum inhibitory concentrations of methicillin-resistant Staphylococcus aureus on mortality in patients with nosocomial pneumonia. Can J Infect Dis Med Microbiol (2013) 24(3): e75-9.
27. Vandecasteele SJ, De Vriese AS, Tacconelli E. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother (2013) 68(4):743-8. doi:10.1093/jac/dks495
28. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet (2006) 45(8):755-73. doi:10.2165/00003088-200645080-00001
29. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.Antimicrob Agents Chemother (2008) 52(4):1330-6. doi:10.1128/ AAC.01602-07
30. Bonten MJ, Slaughter S, Ambergen AW, Hayden MK, van Voorhis J, Nathan C, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med (1998) 158(10):1127-32. doi:10.1001/archinte.158.10.1127
31. Bonten MJ,WillemsR,WeinsteinRA.Vancomycin-resistant enterococci: whyare they here, and where do they come from? Lancet Infect Dis (2001) 1(5):314-25. doi:10.1016/S1473-3099(01)00145-1
32. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med (2000) 342(10):710-21. doi:10.1056/NEJM200003093421007
33. CourvalinP.Vancomycin resistance in gram-positive cocci.Clin Infect Dis (2006) 42(Suppl 1):S25-34. doi:10.1086/491711
34. Boyd DA, Willey BM, Fawcett D, Gillani N, Mulvey MR. Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel d-Ala-d-Ser gene cluster, vanL. Antimicrob Agents Chemother (2008) 52(7):2667-72. doi:10.1128/AAC.01516-07
35. Yoon YK, Lee SE, Lee J, Kim HJ, Kim JY, Park DW, et al. Risk factors for prolonged carriage of vancomycin-resistant Enterococcus faecium among patients in intensive care units: a case-control study. J Antimicrob Chemother (2011) 66(8):1831-8. doi:10.1093/jac/dkr204
36. Polgreen PM, Yang M, Kuntz JL, Laxminarayan R, Cavanaugh JE. Using oral vancomycin prescriptions as a proxy measure for Clostridium difficile infections: a spatial and time series analysis. Infect Control Hosp Epidemiol (2011) 32(7):723-6. doi:10.1086/660858
37. Currie BP, Lemos-Filho L. Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycin-resistant enterococci. Antimicrob Agents Chemother (2004) 48(11):4427-9. doi:10.1128/AAC.48.11.4427-4429.2004
38. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 52(1):31-40. doi:10.1093/cid/ ciq031
39. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med (2006) 166(19):2138-44. doi:10.1001/ archinte.166.19.2138
40. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis (2006) 42(Suppl 1):S35-9. doi:10.1086/491712
41. Knudsen JD, Fuursted K, Espersen F, Frimodt-Møller N. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob Agents Chemother (1997) 41(9):1910-5.
42. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet (2004) 43(13):925-42. doi:10.2165/00003088-200443130-00005
43. Kullar R, Leonard SN, Davis SL, Delgado G Jr, Pogue JM, Wahby KA, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy (2011) 31(5):441-8. doi:10.1592/phco.31. 5.441
44. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2013) 57(4):1654-63. doi:10.1128/AAC.01485-12
45. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet (1986) 11(4):257-82. doi:10.2165/00003088-198611040- 00001
46. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother (1984) 25(4):433-7. doi:10.1128/AAC.25.4.433
47. Rodvold KA, Blum RA,Fischer JH, Zokufa HZ,Rotschafer JC, Crossley KB,et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother (1988) 32(6):848-52. doi:10.1128/AAC.32. 6.848
48. Golper TA, Noonan HM, Elzinga L, Gilbert D, Brummett R, Anderson JL, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther (1988) 43(5):565-70. doi:10.1038/ clpt.1988.74
49. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis (2007) 45(3):302-7. doi:10.1086/519265
50. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf (2010) 9(1):9-14. doi:10.1517/14740330903413514
51. Polk RE, Healy DP, Schwartz LB, Rock DT, Garson ML, Roller K. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis (1988) 157(3):502-7. doi:10.1093/infdis/157.3.502
52. Wong JT, Ripple RE, MacLean JA, Marks DR, Bloch KJ. Vancomycin hypersensitivity: synergism with narcotics and "desensitization" by a rapid continuous intravenous protocol. J Allergy Clin Immunol (1994) 94(2 Pt 1):189-94. doi:10.1053/ai.1994.v94.a55251
53. Renz CL, Thurn JD, Finn HA, Lynch JP, Moss J. Antihistamine prophylaxis permits rapid vancomycin infusion. Crit Care Med (1999) 27(9):1732-7. doi:10.1097/00003246-199909000-00006
54. Black E, Lau TT, Ensom MH. Vancomycin-induced neutropenia: is it doseor duration-related? Ann Pharmacother (2011) 45(5):629-38. doi:10.1345/aph. 1P583
55. Von Drygalski A, Curtis BR, Bougie DW, McFarland JG, Ahl S, Limbu I, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med (2007) 356(9):904-10. doi:10.1056/NEJMoa065066
56. Christie DJ, van Buren N, Lennon SS, Putnam JL. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood (1990) 75(2):518-23.
57. Yazganoglu KD, Ozkaya E, Ergin-Ozcan P, Cakar N. Vancomycin-induced drug hypersensitivity syndrome. J Eur Acad Dermatol Venereol (2005) 19(5):648-50. doi:10.1111/j.1468-3083.2005.01228.x
58. Hassaballa H, Mallick N, Orlowski J. Vancomycin anaphylaxis in a patient with vancomycin-induced red man syndrome. Am J Ther (2000) 7(5):319-20. doi:10.1097/00045391-200007050-00010
59. Hsiao SH, Chou CH, Lin WL, Lee EJ, Liao LH, Chang HJ, et al. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy. J Clin Pharm Ther (2012) 37(3):296-300. doi:10.1111/j.1365-2710.2011.01291.x
60. Ben m'rad M, Leclerc-Mercier S, Blanche P, Franck N, Rozenberg F, Fulla Y, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) (2009) 88(3):131-40. doi:10.1097/ MD.0b013e3181a4d1a1
61. Vauthey L, Uçkay I, Abrassart S, Bernard L, Assal M, Ferry T, et al. Vancomycin-induced DRESS syndrome in a female patient. Pharmacology (2008) 82(2):138-41. doi:10.1159/000142729
62. Young S, Ojaimi S, Dunckley H, Douglas MW, Kok J, Fulcher DA, et al. Vancomycin-associated drug reaction with eosinophilia and systemic symptoms syndrome. Intern Med J (2014) 44(7):694-6. doi:10.1111/imj.12462
63. Bernstein EF, Schuster M. Linear IgA bullous dermatosis associated with vancomycin. Ann Intern Med (1998) 129(6):508-9. doi:10.7326/0003-4819-129-6- 199809150-00022
64. Nousari HC, Kimyai-Asadi A, Caeiro JP, Anhalt GJ. Clinical, demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin. Report of 2 cases and review of the literature. Medicine (Baltimore) (1999) 78(1):1-8. doi:10.1097/00005792-199901000-00001
65. Klein PA, Callen JP. Drug-induced linear IgA bullous dermatosis after vancomycin discontinuance in a patient with renal insufficiency. J Am Acad Dermatol (2000) 42(2 Pt 2):316-23. doi:10.1016/S0190-9622(00)90102-6
66. Marik PE, Ferris N. Delayed hypersensitivity reaction to vancomycin. Pharmacotherapy (1997) 17(6):1341-4.
67. Smith PF, Taylor CT. Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions. Pharmacotherapy (1999) 19(2):240-4. doi:10.1592/phco.19.3.240.30912
68. Wazny LD, Daghigh B. Desensitization protocols for vancomycin hypersensitivity. Ann Pharmacother (2001) 35(11):1458-64. doi:10.1345/aph.1A002
69. Lin RY. Desensitizationinthe managementofvancomycinhypersensitivity.Arch InternMed (1990) 150(10):2197-8. doi:10.1001/archinte.1990.00390210145031
70. Corey GR, Kabler H, Mehra P,Gupta S,Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med (2014) 370(23):2180-90. doi:10.1056/NEJMoa1310422
71. Corey GR, Kollef MH, Shorr AF, Rubinstein E, Stryjewski ME, Hopkins A, et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother (2014) 58(4):2030-7. doi:10.1128/AAC. 02330-13
72. Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, et al. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. J Antimicrob Chemother (2012) 67(6):1496-502. doi:10.1093/jac/dks081
73. Stryjewski ME, Chu VH, Cabell CH, Fowler VG. Issues in the management of endocarditis caused by resistant gram-positive organisms. Curr Infect Dis Rep (2004) 6(4):283-91. doi:10.1007/s11908-004-0049-7
74. Stryjewski ME,LentnekA,O'RiordanW,PullmanJ,Tambyah PA,Miró JM,et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the assure study. BMC Infect Dis (2014) 14:289. doi:10.1186/1471-2334-14-289
75. Rubinstein E, Corey GR, Stryjewski ME, Kanafani ZA. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia. Expert Opin Pharmacother (2011) 12(17):2737-50. doi:10.1517/ 14656566.2011.633511
76. Chavanet P. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. Med Mal Infect (2013) 43(11-12):451-5. doi:10.1016/j.medmal.2013.09.011